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Suppression of Spontaneous Dermatitis in
NC/Nga Murine Model by PG102 Isolated from
Actinidia arguta
Eun-Jin Park1, Kyoung Chul Park1, Haekwan Eo1, Jangkyun Seo2, Miwon Son3, Kyu Han Kim4, Yoon-Seok
Chang5, Sang-Heon Cho5, Kyung-Up Min5, Mirim Jin6 and Sunyoung Kim2
Atopic dermatitis (AD) is a chronic inflammatory skin disease, which requires safe and effective
pharmacological therapy. We previously found that two preparations from Actinidia arguta, PG102T, and
PG102E, could modulate Th1/Th2 pathways and suppress IgE biosynthesis. This study was performed to assess
the therapeutic effects of PG102T and PG102E on the development of dermatitis in NC/Nga mice, characterized
by the spontaneous onset of AD along with an elevated level of IgE under conventional conditions. PG102T or
PG102E administration significantly reduced dermatitis severity as well as scratching tendency in conventional
mice. The suppression of dermatitis by PG102 was accompanied by a decrease in the plasma level of IgE, IgG1,
and IL-4 and also by an increase in that of IgG2a and IL-12. The splenic level of IL-4, IL-5, and IL-10 was
downregulated, whereas that of IFN-g and IL-12 was increased. The number of eosinophils and the expression of
eotaxin and thymus and activation-regulated chemokine were decreased by PG102T or PG102E. Histological
findings also indicated that the thickening of epidermis/dermis and the dermal infiltration of inflammatory cells
including mast cells were greatly inhibited. These data suggest that PG102 may be effective therapeutic agents
for the treatment of AD.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory skin disease
characterized by pruritic and eczematous skin lesions, along
with elevated IgE levels, and its incidence is globally
increasing in infants and children (Sampson, 1992; Leung,
1997). Among many cell types involved in the pathogenesis
of AD, Th2 cells producing IL-4, IL-5, IL-10, and IL-13 play a
critical role in the initiating phase of disease progression
(Spergel et al., 1999; Leung and Soter, 2001). Th1-type
cytokines, such as IFN-g, are also found in the skin lesions of
AD during the later stage of the disease, but the development
of AD is thought to be caused primarily by the over-
production of Th2-mediated cytokines, chemokines (includ-
ing eotaxin and thymus and activation-regulated chemokine
(TARC)), and IgE, as well as the defective production of IFN-g
and IL-12 (Spergel et al., 1999; Vestergaard et al., 1999;
Sandoval-Lopez and Teran, 2001; Chen et al., 2004).
NC/Nga mice were established in 1957 based on Japanese
fancy mice (Nishiki-Nezumi). When kept under specific
pathogen-free (SPF) conditions, mice remain normal and
healthy. However, when placed in conventional surround-
ings, clinical signs begin with scratching behavior and IgE
elevation starting from the age of 8 weeks followed by the
onset of the eczematous condition along with the infiltration
of various inflammatory cells in the skin lesions (Matsuda
et al., 1997; Spergel et al., 1999; Vestergaard et al., 1999,
2000; Nakatani et al., 2001; Sandoval-Lopez and Teran,
2001; Ma et al., 2002; Heishi et al., 2003). These findings
resemble the various characteristic inherent to AD patients,
suggesting the NC/Nga mouse can be an excellent animal
model for human AD and also that the modulation of Th1/
Th2 and the suppression of IgE biosynthesis may be a
therapeutic strategy that can fundamentally improve the
clinical symptoms of AD in both humans and mice.
We recently discovered that PG102 prepared from
Actinidia arguta, generally called hardy kiwifruit, contains
an orally active immune-modulating activity in the
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OVA-sensitized murine model (Park et al., 2005). In this
study, we used the NC/Nga murine model to examine the
possible use of PG102 as a therapeutic agent for AD. Oral
administration of PG102T or PG102E highly suppressed the
production of IgE, IgG1, IL-4, and IL-5, while increasing that
of IgG2a, IL-12, and IFN-g in plasma and/or splenocytes. Both
PG102T and PG102E decreased the plasma levels of eotaxin
and TARC and the number of eosinophils, resulting in the
prevention of eosinophilia. Histological analysis indicated
that PG102T or PG102E inhibited the infiltration of inflam-
matory cells in the dermis. These results indicated that
PG102T and PG102E might be useful for the treatment of AD.
RESULTS
Oral administration of PG102T and PG102E inhibits the
development of spontaneous dermatitis in conventional NC
mice
To examine the possible effects of PG102 on AD, conven-
tional NC mice were orally administrated with PG102T
(50 mg (60 U)/kg/day), PG102E (5 mg (54.5 U)/kg/day), dex-
amethasone (DEX) (2.5 mg/kg/day), or distilled water (DW)
(100 ml/mouse/day) on a daily basis for 7 weeks, and the
progression of AD was observed. The increase in the
dermatitis severity scores of conventional NC mice treated
with DW showed that the development of dermatitis
progressed in an age-dependent manner (Figure 1a). How-
ever, treatment with PG102T or PG102E significantly
decreased the score from 9 weeks of age. The improvement
of dermatitis severity was accompanied by a reduction in
scratching incidence. PG102T or PG102E administration
greatly lowered the scratching time from 9 weeks of age
(Figure 1b). Moreover, these outcomes were consistent with
the observation made through the analysis of the overall
clinical visual features of the mice (Figure 1c). DEX also
decreased the dermatitis severity and scratching behavior.
These data indicated that PG102T and PG102E might
suppress the spontaneously induced dermatitis in this animal
model.
PG102T and PG102E decrease the production of IgE and IgG1,
while increasing that of IgG2a in plasma
In addition to the visual clinical features imitating human AD,
conventional NC mice also show elevated levels of IgE in
plasma after the onset of dermatitis. Therefore, it was tested
whether PG102T or PG102E could control the plasma level
of Th2-mediated IgE and IgG1 and Th1-mediated IgG2a.
Under SPF conditions, NC mice normally produced approxi-
mately 150 ng/ml of total IgE, but when animals were placed
under conventional conditions, IgE levels gradually increased
with age, to almost 17 mg/ml at 14 weeks of age. Adminis-
tration of PG102T or PG102E lessened the plasma level of IgE
from 10 weeks of age in a statistically significant manner,
resulting in a 5-fold lower level of IgE at the end of the
experiment. The IgE-lowering effect of PG102T and PG102E
was comparable to that of DEX (Figure 2a). At 12 weeks of
age, the level of IgG1 and IgG2a was measured. Conven-
tional NC mice treated with DW produced a level of IgG1
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Figure 1. Effects of PG102T and PG102E on the development of dermatitis
in NC mice. (a) Dermatitis index, (b) scratching incidence, and (c) clinical
features were assessed by the criteria described in Materials and Methods.
Values are expressed as means7SEM of 8–10 animals. (a) i**: 9–14 weeks,
ii**: 10–14 weeks, iii**: 9–10 weeks/*: 11–14 weeks, (b) i**ii**: 9–13 weeks,
iii**: 9–10 weeks/*:12–13 weeks. *, Po0.05; **, Po0.01, vs DW-treated NC
mice. Bar¼ (a) index, (b) sec.
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Figure 2. Effects of PG102T and PG102E on the plasma levels of IgE and
IgG2a in NC mice. (a) The levels of IgE and (b) two IgG subtypes were
measured in plasma obtained from animals at the age of 7, 10, 12, 14 weeks
and 12 weeks, respectively. Values are expressed as mean7SEM of 8–10
animals. *Po0.05; **Po0.01, vs DW-treated NC mice. Bar¼ (a) mg/ml.
www.jidonline.org 1155
E-J Park et al.
Suppression of Atopic Dermatitis by PG102
greater than 5 mg/ml. However, PG102T and PG102E
decreased its level by almost 75 and 90%, respectively. In
contrast, the level of IgG2a was increased in animals treated
with PG102T or PG102E (Figure 2b). These data indicated
that PG102T and PG102E might suppress the development of
dermatitis by lowering the level of IgE and IgG1 and by
increasing that of IgG2a.
PG102T and PG102E regulate the balance of Th1/Th2 cytokine
production in plasma and splenocytes
The above data indicated that PG102T and PG102E might
affect the expression of Th1 and Th2 cytokines. To under-
stand the molecular basis of PG102T and PG102E, the level
of two cytokines, IL-4 and IL-12, each representing the Th2
and Th1 pathways, was measured in plasma at 12 weeks of
age. Compared with conventional NC mice treated with DW,
the level of IL-4 was lowered in mice treated with PG102T or
PG102E by 60 and 76%, respectively. Administration of
PG102T or PG102E elevated the level of IL-12 in a
statistically significant manner (Table 1a).
Next, we analyzed the effects of PG102T and PG102E on
the production of Th1 and Th2 cytokines in splenocytes
isolated from NC mice at 14 weeks of age (Table 1b). In the
presence of concanavalin A (ConA), the level of Th2
cytokines produced by splenocytes was highly elevated, but
PG102T or PG102E reduced the levels of IL-4, IL-5, and IL-10
by 21–78%. DEX also inhibited the levels of all three Th2
cytokines, although the decrease of IL-5 by DEX was not
statistically significant. The level of IL-13 was significantly
influenced by neither PG102 nor DEX.
When cells from conventional NC mice were grown in the
presence of ConA, the levels of IL-12 and IFN-g were
augmented (Table 1b). In SPF NC mice, the level of IL-12 was
166 pg/ml, but the stimulation with ConA increased that by
4-fold. Administration of PG102T or PG102E further induced
its level by approximately 150 or 250%, respectively. The
level of IFN-g was also dramatically increased in the presence
of ConA to almost 11 ng/ml. PG102T or PG102E further
elevated the level of this cytokine. DEX potently suppressed
the level of IL-12, whereas it did not affect that of IFN-g. In
summary, PG102T and PG102E increased the level of Th1
cytokines, whereas decreasing that of selective Th2 cyto-
kines, unlike DEX.
PG102T and PG102E not only prevent eosinophilia, but also
decrease the level of eotaxin and TARC
Dermal infiltration of inflammatory cells including eosino-
phils is an important feature of AD in NC mice (Matsuda
et al., 1997). Because the presence of inflammatory cells in
the skin lesions may have resulted from their mobilization
from bone marrow into blood, we first analyzed the number
of total leukocytes and eosinophils in the peripheral blood at
12 weeks of age. As shown in Table 2, the number of total
leukocytes of conventional NC mice was increased upon the
Table 1. Effects of PG102T and PG102E on the level of Th1 and Th2 cytokines in plasma and cultured splenocytes
(a) Plasma levels (pg/ml)
Mouse IL-4 IL-12
Conventional
DW 474731 (100) 859717 (100)
PG102T 189764 (40)** 12177140 (142)*
PG102E 113769 (24)** 1106777 (129)*
DEX 80756 (17)** 2367140 (27)**
SPF (naı¨ve) 1375 (3) 17087116 (199)
(b) Splenic levels (pg/ml)
Mouse IL-4 IL-5 IL-10 IL-13 IL-12 IFN-c
Conventional
DW 134717 (100) 680798 (100) 782721 (100) 44871 (100) 656771 (100) 104077160 (100)
PG102T 3076 (22)** 337752 (53)* 62171 (79)* 34877 (78) 957768 (146)* 1584872704 (152)*
PG102E 5477 (40)** 20376 (30)** 594719 (76)* 406711 (91) 1636742 (249)** 1805071380 (173)**
DEX 54711 (40)** 5317283 (78) 416730 (53)** 417729 (93) 149722 (23)** 100967236 (97)
SPF (naı¨ve) 1272 (9) 3378 (5) 3773 (5) ND 16671 (25) 390788 (4)
DEX, dexamethasone; DW, distilled water; ND, not detectable; SPF, specific pathogen-free.
Plasma samples were isolated from each group of mice at the age of 12 weeks.
All splenocytes from NC mice were stimulated with ConA during the culture. Values are expressed as means7SEM for 8–10 animals.
The numbers in the parenthesis were calculated as a relative percentage for the value of DW-treated conventional NC mice.
*Po0.05 and **Po0.01, vs DW-treated NC mice (Student’s t-test).
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onset of dermatitis. In particular, the number of eosinophils
was greatly increased in DW-treated mice under conven-
tional conditions, resulting in eosinophilia. However,
PG102T or PG102E administration lowered the number of
both total leukocytes and eosinophils, presumably contribut-
ing to the prevention of eosinophilia. DEX also significantly
reduced the number of these cells.
The changes in the number of circulating eosinophils may
be manifested by the production of chemokines, leading to
chemoattraction in response to inflammation (Vestergaard
et al., 1999; Nakatani et al., 2001; Sandoval-Lopez and
Teran, 2001; Ma et al., 2002). Therefore, the plasma levels of
eotaxin and TARC, which are representative chemoattrac-
tants for eosinophils and Th2 cells, were determined.
Conventional NC mice treated with DW produced an
increased level of eotaxin and TARC, but these levels were
decreased in PG102T- or PG102E-treated mice by approxi-
mately 25–45% (Table 2). These results showed that PG102T
and PG102E inhibited the production of eotaxin and TARC,
resulting in the prevention of Th2-mediated eosinophilia.
PG102T and PG102E inhibit the infiltration of inflammatory
cells in dermis and the thickening of the epidermis/dermis
Improvement of clinical skin condition and inhibition of Th2
response by PG102T and PG102E were also confirmed by the
analysis of hematoxylin and eosin and toluidine blue stained
sections at 14 weeks of age. NC mice fed with DW exhibited
a marked thickening of the epidermis and dermis, prominent
hyperkeratosis, infiltration of inflammatory cells, particularly
mast cells, and hemorrhage (Figure 3b and g; arrow).
However, treatment with PG102T or PG102E for 7 weeks
inhibited the thickening of the epidermis/dermis and the
infiltration of inflammatory cells in the dermis (Figure 3c, d,
h, and i), resulting in a histological environment very similar
to that of SPF NC mice. Administration of DEX also produced
similar results, but greatly expanded the adipocyte region
(Figure 3e). Measurement of epidermal and dermal thickness
in face and back skin also demonstrated that both PG102T
and PG102E prevented hyperplasia of the epidermis and
dermis in a statistically significant manner (data not shown).
These results indicated that oral intake of PG102T or PG102E
could effectively suppress the development of dermatitis in
NC mice with little or no side effects.
PG102 and PG102E reduce the expression of Th2-mediated
cytokines and chemokines
To investigate the effects of PG102T or PG102E on the Th2-
mediated production of cytokines and chemokines in the
skin, the level of IL-4, IL-5, eotaxin, and TARC was measured
by ELISA at 14 weeks of age. In the skin from SPF NC mice,
all four proteins were weakly expressed, but their levels were
notably increased in conventional NC mice. Administration
of PG102T or PG102E lowered the levels of IL-4, eotaxin, and
TARC by more than 30%. The effect on IL-5 expression was
more prominent, with its level being decreased by almost
90%. On the contrary, DEX inhibited the levels of IL-5 and
TARC, but not that of IL-4 and eotaxin (Figure 3k). These
results demonstrated that PG102T and PG102E downregu-
lated the level of Th2-specific cytokines and chemokines,
leading to the inhibition of skin inflammation by the
chemoattraction for inflammatory cells.
DISCUSSION
AD is a major allergic disease resulting from dermal
inflammation caused by an abnormal immune response, in
particular, overactivation of the Th2 pathway (Sampson,
1992; Leung, 1997; Leung and Soter, 2001). Although the
etiology and pathology of AD are not fully understood, it has
been reported that natural immune modulators from herbal
extracts or herbal derivatives may have a therapeutic effect
on AD through various experimental and clinical investiga-
tions (Kotani et al., 2000; Ziment and Tashkin, 2000; Oku
and Ishiguro, 2001). Recently, we also found that a water-
soluble extract from A. arguta, PG102, controls the produc-
tion of selective Th1- and Th2-mediated cytokines and also
that of IgE in the OVA-sensitized mouse model (Park et al.,
Table 2. Effects of PG102T and PG102E on the number of eosinophils and the production of eotaxin and TARC in
peripheral blood
Mouse Cell (105 cells/ml) Chemokine (pg/ml)
Total leukocyte Eosinophil Eotaxin TARC
Conventional
DW 56.771.9 (100) 3.970.9 (100) 945.97139.6 (100) 77.878 (100)
PG102T 39.476.1 (69) 0.670.5 (15)** 721.4796.9 (76) 48.677.7 (62)*
PG102E 28.874.2 (51)* 0.470.01 (10)** 530.8763.8 (56)* 47.473.1 (61)*
DEX 2373.3 (41)** 0.870.2 (21)** 705.5786.8 (75) 55.173.0 (71)
SPF (naı¨ve) 42.6711.8 (75) 0.370.2 (8) 709.1762 (75) 45.571.2 (59)
DEX, dexamethasone; DW, distilled water; SPF, specific pathogen-free; TARC, thymus and activation-regulated chemokine.
Blood samples were isolated from each group of mice at the age of 12 weeks.
Values are expressed as means7SEM for 8–10 animals.
The numbers in the parenthesis were calculated as a relative percentage for the value of DW-treated conventional NC mice.
*Po0.05 and **Po0.01, vs DW-treated mice (Student’s t-test).
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2005). Based on these data, we investigated whether PG102
could produce any actual therapeutic effect(s) on AD using
NC mice.
Our results indicated that PG102T and PG102E sup-
pressed the development of spontaneously induced derma-
titis, probably by controlling various Th1- and Th2-associated
factors, namely the downregulation of IL-4, IL-5, IL-10, and
IgE, as well as the upregulation of IL-12, IFN-g, and IgG2a.
The cell biological consequences of such changes in this
model include the highly decreased number of eosinophils,
the suppression of the thickening of the epidermis and
dermis, and the inhibition of the infiltration of various
inflammatory cells including mast cells. Of particular interest
is a decrease in the regional expression levels of eotaxin,
TARC, IL-4, and IL-5. Eotaxin, together with IL-5, is known to
be a potent chemoattractant for eosinophils, whereas TARC
produced by Th2 cells and keratinocytes is thought to attract
Th2 cells, and induces the pathological responses typically
associated with AD. In this regard, it is worth noting that the
receptors for eotaxin and TARC are CC-chemokine receptor 3
(CCR3) and CCR4, respectively, which are both highly
expressed in Th2 cells (Spergel et al., 1999; Vestergaard
et al., 1999; Nakatani et al., 2001; Sandoval-Lopez and
Teran, 2001; Ma et al., 2002; Chen et al., 2004).
The detailed molecular mechanism(s) underlying the
therapeutic effects of PG102, observed in the NC/Nga mouse
model, remains to be elucidated. Based on PG102-mediated
suppression of GATA-binding protein 3 (GATA-3) and
phosphorylated signal transducer and activator of transcrip-
tion-6 in the skin lesions of NC mice (data not shown), it is
possible that PG102 may act first on these cellular transcrip-
tion factors and subsequently on the expression of Th2
cytokines such as IL-4 and IL-5, initiating the cascade
reaction that eventually leads to a decrease in the level of
IgE and respective chemokines. It was reported that GATA-3
plays a critical role in the expression of Th2-specific
cytokines (IL-4 and IL-5) and chemotactic receptors such as
CCR4 and chemoattractant receptor-homologus molecule
expressed on Th2 cells (CRTH2) (Sundrud et al. 2003). It is
also possible that PG102 contains multiple bioactive
compounds, acting on several different steps in the allergy-
related pathways.
Whatever the actual mechanism(s) of PG102 is, the results
from NC mice suggest that PG102 has great potential as a safe
and effective reagent for the treatment of AD. Given the fact
that the prevalence of allergic diseases including AD is
steadily increasing in all major developed countries and
virtually no reagent is available for the fundamental treatment
of AD, further investigation into PG102 is warranted at the
detailed molecular level.
MATERIALS AND METHODS
Animals
SPF female NC/Nga mice were purchased from SLC (Tokyo, Japan).
Mice (5–6 weeks old) were maintained in a SPF environment (SPF
NC mice) and acclimated for at least 1 week before use. Seven-
week-old, SPF NC mice were moved to an air-uncontrolled
conventional room (conventional NC mice). Animal experiments
complied with the University Animal Care and Use Committee
guidelines at Seoul National University.
Preparation of PG102T and PG102E
The PG102T and PG102E used in this study were prepared from A.
arguta, and specific units of each preparation were calculated as
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Figure 3. Effects of PG102T and PG102E on the skin lesions in NC mice.
(a–e) Skin biopsies of mice were stained with hematoxylin and eosin
and (f–j) toluidine blue. The microscope original magnification is (a–e)  100
and (f–j)  400. In the protein samples from skin biopsies, the level of IL-4,
IL-5, eotaxin, and (k) TARC was measured by ELISA. Values are expressed as
mean7SEM of five animals. *Po0.05; **Po0.01, vs DW-treated NC mice.
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described previously (Park et al., 2005). Briefly, the dried fruit was
extracted by boiling in DW to prepare PG102T. For the preparation
of ethylacetate fraction (PG102E), PG102T were extracted first with
chloroform and then with ethylacetate. PG102T and its ethylacetate
fraction were filtered, concentrated, and freeze-dried. Each prepara-
tion was dissolved in DW and 50% ethanol, respectively, and stored
at 801C until use. Specific units of PG102T and PG102E were
calculated from the results of bioassay based on their inhibitory
activity on the production of IL-4 in OVA-stimulated splenocytes.
Both PG102T and PG102E contained undetectable levels of
endotoxin as determined by the Limulus amebocyte lysate assay
(Sigma, St Louis, MO).
Oral administration of PG102T or PG102E
Conventional NC mice were divided into four groups (n¼ 8–10/
group) and were orally treated with PG102T (50 mg/kg/day), PG102E
(5 mg/kg/day), DEX (2.5 mg/kg/day, Sigma), or distilled water (DW;
100ml/mouse/day) once a day from the age of 7 to 14 weeks. SPF NC
mice, as a negative control, received DW. The dosages of PG102T
and PG102E used in this experiment are the minimal concentrations
having maximal activity in the preliminary dose–response experi-
ment.
Effects of PG102T or PG102E on the development of dermatitis
in NC mice
The dermatitis severity of mice was assessed once a week for 7
weeks by two persons unaware of which mice belonged to which
group, according to a slight modification of the criteria described by
Leung et al. (1990). Itching time was observed for 20 minutes per
mouse for the evaluation of scratching incidence. A total clinical
score of dermatitis severity was defined as the sum of the individual
scores graded as 0 (none), 1 (mild), 2 (moderate), and 3 (severe) for
each of five signs and symptoms (itch, erythema/hemorrhage,
edema, excoriation/erosion, and scaling/dryness).
Measurement of plasma level of Igs, cytokines, and chemokines
Spontaneously induced allergic responses were monitored by
measuring the plasma levels of Igs including IgE, IgG1, and IgG2a,
cytokines, and chemokines. Blood was collected from the retro-
orbital plexus with glass capillary tubes at the age of 7, 10, 12, and
14 weeks, and separated plasma samples were stored at 801C until
use. The level of IgE was determined by a mouse IgE detection kit
(Shibayagi, Gunma, Japan) and that of IgG1 and IgG2a (Bethyl
Laboratories, Montgomery, TX) was measured by the sandwich
ELISA method as described by Hirano et al. (1989). The plasma
levels of mouse IL-4, IL-12, eotaxin and TARC were also measured
by ELISA kits (Endogen, Cambridge, MA and R&D Systems,
Minneapolis, MN).
Th1/Th2 cytokine production by splenocytes derived from NC
mice
At the age of 14 wks, NC mice were killed by decapitation. To study
the production of cytokines by splenocytes, spleens of an individual
group were obtained, and isolated splenocytes were resuspended in
culture medium (Rosewell Park Memorial Institute-1640 containing
with 10% fetal bovine serum (Life Technologies, Grand Island, NY)).
Splenocyte suspension was seeded (5 106 cells/ml/well), and then
incubated in the absence or presence of ConA (Sigma) at 2 mg/ml for
3 days. The concentration of ConA was optimized from the
preliminary dose–response experiments, and no cytotoxicity was
found at the concentration used in this experiment. Following
incubation, the supernatants were collected to determine the level of
cytokines (IL-4, IL-5, IL-10, IL-12, IL-13, and IFN-g) by ELISA kits
(Endogen and R&D systems).
Analysis of total leukocytes and eosinophils in peripheral blood
At 14 weeks of age, blood was collected from an individual group of
mice. The number of total leukocytes and eosinophils in the
heparinized blood was counted using a Celldyn hemocytometer
(Abbott; Santa Clara, CA).
Histological analysis and measurement of epidermal and dermal
thickness in AD-like skin lesions
For histological examination, small biopsies were obtained from the
face and dorsal skin of NC mice (n¼ 5/group) at the age of 14 weeks.
Skin sections were fixed in 10% phosphate-buffered formalin (pH
7.2), embedded in paraffin, cut at 4mm, and stained with
hematoxylin and eosin and toluidine blue for detecting various
inflammatory cells and mast cells, respectively. Cells in dermis were
observed under a microscope at a magnification of  100
(hematoxylin and eosin) and  400 (toluidine blue).
Determination of cytokine and chemokine expression in the
skin biopsies
The levels of IL-4, IL-5, eotaxin, and TARC in the skin biopsies from
the face of mice were measured by ELISA method as described by
Kim et al. (2003). Briefly, the tissue from facial skin lesions was
excised, homogenized in lysis buffer, and then the freezing/thawing
procedure was repeated three times. After centrifugation, the
supernatants containing total cellular protein were quantified and
used to detect the level of cytokines and chemokines. Results were
normalized to the total amount of protein prepared from tissue
lysates.
Statistics
Data were expressed as mean7SEM, and differences between mean
values were analyzed by unpaired Student’s t-test. P-values less than
0.05 or 0.01, which were calculated as one-tailed P-values, were
considered statistically significant.
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